The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

HPLC-MS analysis identified hundreds of components in Androctonus scorpion venoms, with disulfide-rich peptides being abundant. All three scorpion venoms exhibited hyaluronidase activity, while ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

As of Wednesday, December 24, Agios Pharmaceuticals, Inc.’s AGIO share price has surged by 16.31%, which has investors questioning if this is right time to sell.

Want to support independent women's media? Become a Mamamia subscriber and get an all-access pass to everything we make, ...

Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors ...